| Title: |
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis |
| Authors: |
Peloquin, Charles A; Phillips, Patrick PJ; Mitnick, Carole D; Eisenach, Kathleen; Patientia, Ramonde F; Lecca, Leonid; Gotuzzo, Eduardo; Gandhi, Neel R; Butler, Donna; Diacon, Andreas H; Martel, Bruno; Santillan, Juan; Hunt, Kathleen Robergeau; Vargas, Dante; von Groote-Bidlingmaier, Florian; Seas, Carlos; Dianis, Nancy; Moreno-Martinez, Antonio; Kaur, Pawandeep; Horsburgh, C Robert |
| Source: |
Antimicrobial Agents and Chemotherapy, vol 62, iss 10 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2018 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
3214 Pharmacology and Pharmaceutical Sciences (for-2020); 32 Biomedical and Clinical Sciences (for-2020); Rare Diseases (rcdc); Infectious Diseases (rcdc); Tuberculosis (rcdc); Emerging Infectious Diseases (rcdc); 3 Good Health and Well Being (sdg); Adolescent (mesh); Adult (mesh); Aged (mesh); Antitubercular Agents (mesh); Area Under Curve (mesh); Female (mesh); Humans (mesh); Levofloxacin (mesh); Male (mesh); Middle Aged (mesh); Mycobacterium tuberculosis (mesh); Tuberculosis (mesh); Tuberculosis; Multidrug-Resistant (mesh); Young Adult (mesh); levofloxacin; pharmacokinetics; antitubercular agents |
| Subject Geographic: |
10.1128/aac.00770 - 10.1128/aac.00718 |
| Description: |
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.). |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt4q4558jx; https://escholarship.org/uc/item/4q4558jx; https://escholarship.org/content/qt4q4558jx/qt4q4558jx.pdf |
| DOI: |
10.1128/aac.00770-18 |
| Availability: |
https://escholarship.org/uc/item/4q4558jx; https://escholarship.org/content/qt4q4558jx/qt4q4558jx.pdf; https://doi.org/10.1128/aac.00770-18 |
| Rights: |
public |
| Accession Number: |
edsbas.B305542E |
| Database: |
BASE |